Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ixekizumab randomized withdrawal and long-term radiographic outcomes in axial spondyloarthritis
2016-002634-69Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Nov 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial in axial spondyloarthritis (axSpA) and ankylosing spondylitis (AS) comparing Ixekizumab continuation arm with Placebo withdrawal arm (2 arms). Primary endpoint: Proportion without flare during randomized withdrawal retreatment period. Started Nov 2016; status: completed.
02
Drugs
ixekizumab
03
Conditions
axial spondyloarthritis (axSpA)ankylosing spondylitis (AS)
Beyond the preview
Go deeper on 2016-002634-69.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-002634-69.